Swiss Banks Stock News

Idorsia’s pediatric insomnia data puts daridorexant in the spotlight Idorsia (SWX:IDIA) is back on investors’ radar after reporting statistically significant, dose dependent improvements in sleep time for children with insomnia treated with daridorexant, confirming safety and efficacy in patients as young as ten. See our latest analysis for Idorsia. Despite the positive pediatric insomnia data and the recent leadership change in clinical development, Idorsia’s CHF3.524 share price reflects...

Earlier in April 2026, ams-OSRAM reported stronger-than-expected trading, underpinned by improving margins and increased orders for its optical sensor portfolio in automotive and AI applications. The news highlighted how renewed demand for AI-related optical sensors is starting to influence perceptions of ams-OSRAM’s operational progress despite ongoing balance sheet and profitability challenges. We’ll now examine how this renewed interest in AI-related optical sensors could shape...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

SaltX recently reported that it has completed the first industrial-scale test period of electrified precalcination of Holcim’s cement raw meal at its ECRC facility in Hofors, Sweden, achieving positive calcination results and operational stability while processing around 20 tonnes per test run. This progress, alongside parallel work on electrified sintering and a fully electrified pilot plant targeted for 2028, highlights Holcim’s push to electrify and decarbonize cement production at an...

Earnings highlight and why it matters now R&S Group Holding (SWX:RSGN) just released its full year 2025 results, with sales of CHF 414.84 million, revenue of CHF 417.53 million, and net income of CHF 58.1 million drawing fresh attention to the stock. See our latest analysis for R&S Group Holding. The latest results appear to have kept momentum strong, with the share price at CHF24.2 and a 7 day share price return of 22.84% building on a 90 day share price return of 55.33%. The 3 year total...

Julius Bär Gruppe (SWX:BAER) is in the spotlight after a series of leadership changes, including the planned departure of finance chief Evie Kostakis and new board responsibilities for incoming non executive director Colin Bell. See our latest analysis for Julius Bär Gruppe. The executive reshuffle comes as the stock shows mixed momentum, with a 4.9% 1 month share price return and a 1 year total shareholder return of 33.7% contrasting with weaker recent quarterly performance. If leadership...

Medacta Group (SWX:MOVE) has stepped into an unusual spotlight after being selected to engineer a load bearing hip implant for a resurrected Tyrannosaurus rex as part of an international dinosaur revival project. See our latest analysis for Medacta Group. While the dinosaur project has put Medacta in the headlines, the CHF153.4 share price sits below its recent peak, with short term share price returns weaker. However, a 1 year total shareholder return of 34.52% still points to solid long...

Galderma Group (SWX:GALD) is back in focus after new clinical data on Sculptra and Restylane in menopause and medication driven weight loss, fresh nemolizumab results in pediatric atopic dermatitis, and the ALASTIN Signature Practices rollout. See our latest analysis for Galderma Group. The latest clinical readouts and the ALASTIN Signature Practices launch come after a mixed year for the shares, with a 5.83% 1 month share price return, a 3.27% 3 month share price decline, and a 1 year total...

Interest in Holcim (SWX:HOLN) has picked up after partner SaltX reported positive initial results from industrial-scale tests of electrified precalcination of Holcim cement raw meal in Sweden. See our latest analysis for Holcim. The recent electrified precalcination progress comes as Holcim’s share price has risen 12.5% over the past month to CHF72.52, even though the 90 day share price return is a 9.2% decline, while the 1 year total shareholder return of 74.8% and 3 year total shareholder...

C4 Therapeutics recently announced a collaboration with Roche to develop degrader-antibody conjugates for oncology, while Roche also launched its cobas MPX-E blood screening assay in CE-mark accepting countries, consolidating HIV and hepatitis virus detection into a single high-throughput test. Together, these moves underline Roche’s push to pair next-generation cancer modalities with advanced diagnostics that can improve laboratory efficiency and transfusion safety worldwide. We’ll now...

SoftwareOne Holding AG has released its 2025 results, reporting sales of CHF 1,243.4 million and net income of CHF 0.9 million, while proposing a reduced CHF 0.15 per share dividend and setting 2026 guidance for mid-single digit constant-currency revenue growth and a 30%–50% adjusted profit pay-out ratio. Alongside these figures, the company announced a leadership change in human resources, with long-time insider Nina Janorschke stepping in as Chief Human Resources Officer, which may help...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Lonza Group AG ( VTX:LONN ) just reported healthy earnings but the stock price didn't move much. Our analysis suggests...

As European markets experience a positive shift, with the STOXX Europe 600 Index gaining 3.92% amid hopes for a shorter-lived Middle East conflict, investors are keenly observing how energy market volatility and inflation trends might impact dividend stocks. In this context, selecting robust dividend stocks involves considering companies with strong financial health and stable cash flows that can weather economic fluctuations while continuing to provide reliable income streams.

Dividend announcement puts yield in focus for BCGE Banque Cantonale de Genève (SWX:BCGE) has announced an annual dividend of CHF 0.5250 per share, with the stock trading ex dividend on 5 May 2026 and payment scheduled for 7 May 2026. See our latest analysis for Banque Cantonale de Genève. The dividend news follows a strong run in the shares, with a 30 day share price return of 12.38% and a 90 day share price return of 40.48%. The 1 year total shareholder return of 48.30% highlights how...

If you are wondering whether UBS Group's current share price reflects its true worth, you are not alone. That is exactly what this article is here to unpack. UBS Group closed at CHF31.16 recently, with returns of 1.4% over the past 7 days, 4.4% over the past 30 days, a year to date return of negative 18.4%, 39.6% over 1 year, 79.1% over 3 years and 141.6% over 5 years, hinting at shifting expectations around both opportunity and risk. Recent coverage has focused on UBS Group's ongoing...

Wondering if Logitech International at around $73.32 is offering genuine value or just riding sentiment? This article breaks down what the current share price might be implying about the business. The stock has returned 1.3% over the last 7 days and 4.6% over the last 30 days, set against a year to date return of a 7.8% decline and a 25.7% return over 1 year, with a 49.7% return over 3 years and a 21.4% decline over 5 years. Recent coverage has focused on Logitech International as an...

If you are wondering whether Novartis at around CHF123 per share still offers value, the key is to look past the headline price and focus on what you are actually getting for each franc invested. The stock has returned 1.9% over the last week, is roughly flat over 30 days, and has delivered 13.5% year to date alongside 43.2% over 1 year, 65.7% over 3 years, and 96.0% over 5 years. This naturally raises questions about how much of the story is already reflected in the price. Recent attention...

As global markets navigate the complexities of Middle East tensions and energy market volatility, major indices like the Nasdaq Composite have shown resilience with notable gains, reflecting a cautiously optimistic sentiment amid geopolitical uncertainties. In such an environment, growth companies with significant insider ownership often attract attention due to their potential for alignment between management and shareholder interests, which can be particularly appealing when navigating...

As European markets navigate through the complexities of Middle East tensions and energy market volatility, recent gains in indices like the STOXX Europe 600 and Germany’s DAX suggest a cautiously optimistic sentiment among investors. In such an environment, identifying stocks that may be priced below their intrinsic value can offer potential opportunities for those looking to capitalize on market inefficiencies.

As European markets show resilience with the STOXX Europe 600 Index rising by 3.92%, investor sentiment is buoyed by hopes of a shorter-than-expected Middle East conflict and robust gains in major indices like Germany’s DAX and the UK’s FTSE 100. In this environment, growth companies with high insider ownership can offer unique opportunities, as they often signal strong confidence from those closest to the business, aligning their interests with shareholders during volatile times.

Swiss Prime Site (SWX:SPSN) has moved after the company appointed Martina Moosmann as Chief Financial Officer, formalising succession after an interim period and providing investors with fresh information about its senior financial leadership. See our latest analysis for Swiss Prime Site. The appointment appears to have sparked fresh interest, with the share price at CHF138.4 after a 1 day share price return of 1.10% and 7 day share price return of 4.93%. A 90 day share price return of 13.07%...

Roche Holding (SWX:ROP) has received CE marking for its cobas MPX-E assay, enabling simultaneous screening for HIV, hepatitis C, B, and E in blood donations. The company has also launched the cobas eplex RP3 respiratory panel, designed to test for up to 25 respiratory pathogens in a single rapid assay. These diagnostics products target blood safety, laboratory efficiency, and faster respiratory infection diagnosis across clinical settings. Roche Holding, trading at around CHF318.0,...

Amrize (SWX:AMRZ) has completed the acquisition of PB Materials Holdings, adding 26 locations across West Texas. The move increases Amrize’s presence in a region with significant infrastructure and energy related project activity. The transaction reflects Amrize’s push to grow business lines that are less tied to the residential construction cycle. Amrize, listed as SWX:AMRZ, now trades at CHF43.64 per share, with the stock showing a 0.8% decline over the past week and a 1.9% decline year...